share_log

Panbela Therapeutics | 8-K: Current report

Panbela Therapeutics | 8-K: Current report

Panbela Therapeutics | 8-K:重大事件
美股sec公告 ·  04/17 08:39
Moomoo AI 已提取核心信息
On April 16, 2024, Panbela Therapeutics, Inc. announced its decision to delist its common stock from The Nasdaq Stock Market LLC and transition to the OTCQB market, a venture market operated by the OTC Markets Group Inc. The company's board of directors approved the delisting following a Nasdaq hearings panel decision on March 5, 2024, to delist Panbela's stock due to non-compliance with the minimum stockholders' equity requirement. Trading on Nasdaq was suspended on March 7, 2024. Panbela's common stock became eligible for quotation on the OTCQB under the symbol 'PBLA' starting April 17, 2024. The company plans to file a Form 25 with the SEC to deregister its common stock under Section 12(b) of the Securities Exchange Act of 1934, which will not affect its OTCQB eligibility. Panbela also issued a press release on April 16, 2024, detailing the transition and its ongoing clinical development programs for various therapeutics, including ivospemin (SBP-101) and Flynpovi.
On April 16, 2024, Panbela Therapeutics, Inc. announced its decision to delist its common stock from The Nasdaq Stock Market LLC and transition to the OTCQB market, a venture market operated by the OTC Markets Group Inc. The company's board of directors approved the delisting following a Nasdaq hearings panel decision on March 5, 2024, to delist Panbela's stock due to non-compliance with the minimum stockholders' equity requirement. Trading on Nasdaq was suspended on March 7, 2024. Panbela's common stock became eligible for quotation on the OTCQB under the symbol 'PBLA' starting April 17, 2024. The company plans to file a Form 25 with the SEC to deregister its common stock under Section 12(b) of the Securities Exchange Act of 1934, which will not affect its OTCQB eligibility. Panbela also issued a press release on April 16, 2024, detailing the transition and its ongoing clinical development programs for various therapeutics, including ivospemin (SBP-101) and Flynpovi.
2024 年 4 月 16 日,Panbela Therapeutics, Inc. 宣布决定将其普通股从纳斯达克股票市场有限责任公司退市,并过渡到由场外交易市场集团公司运营的风险市场 OTCQB 市场。在纳斯达克听证会小组于 2024 年 3 月 5 日因未遵守最低股东权益要求作出决定将潘贝拉的股票退市后,公司董事会批准了退市。纳斯达克于2024年3月7日暂停交易。从2024年4月17日起,Panbela的普通股有资格在OTCQB上报价,股票代码为 “PBLA”。该公司计划向美国证券交易委员会提交25号表格,根据1934年《证券交易法》第12(b)条注销其普通股,这不会影响其OTCQB资格。Panbela还于2024年4月16日发布了一份新闻稿,详细介绍了包括依沃司佩明(SBP-101)和Flynpovi在内的各种疗法的过渡及其正在进行的临床开发计划。
2024 年 4 月 16 日,Panbela Therapeutics, Inc. 宣布决定将其普通股从纳斯达克股票市场有限责任公司退市,并过渡到由场外交易市场集团公司运营的风险市场 OTCQB 市场。在纳斯达克听证会小组于 2024 年 3 月 5 日因未遵守最低股东权益要求作出决定将潘贝拉的股票退市后,公司董事会批准了退市。纳斯达克于2024年3月7日暂停交易。从2024年4月17日起,Panbela的普通股有资格在OTCQB上报价,股票代码为 “PBLA”。该公司计划向美国证券交易委员会提交25号表格,根据1934年《证券交易法》第12(b)条注销其普通股,这不会影响其OTCQB资格。Panbela还于2024年4月16日发布了一份新闻稿,详细介绍了包括依沃司佩明(SBP-101)和Flynpovi在内的各种疗法的过渡及其正在进行的临床开发计划。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息